Cybin Chief Medical Officer to Present at 2025 Milken Institute Health Summit

Cybin Inc., a Phase 3 clinical-stage neuropsychiatry company developing transformative mental health treatments, announced that Chief Medical Officer Amir Inamdar will participate in a panel discussion at the 2025 Milken Institute Future of Health Summit scheduled for November 4-6, 2025, in Washington, D.C. The company's participation in this prestigious healthcare forum underscores the growing recognition of psychedelic-derived treatments as potential breakthrough options for mental health conditions that affect millions worldwide.

The significance of this speaking engagement lies in Cybin's advanced clinical development pipeline, particularly CYB003, which has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration for adjunctive treatment of major depressive disorder. This designation accelerates the development and review of drugs intended to treat serious conditions when preliminary clinical evidence indicates substantial improvement over available therapies. The company's research pipeline focuses on 5-HT-receptor targeted compounds, representing a novel approach to neuropsychiatry that could potentially offer more effective and durable results for patients struggling with mental health conditions.

Cybin's clinical programs address substantial unmet medical needs in mental healthcare. Major depressive disorder affects approximately 280 million people globally according to World Health Organization data, while generalized anxiety disorder impacts millions more. Current treatment options often provide inadequate relief or come with significant side effects, creating an urgent need for innovative therapeutic approaches. The company's deuterated psilocin analog, CYB003, and deuterated N, N-dimethyltryptamine molecule, CYB004, represent promising investigational treatments that could potentially transform mental healthcare delivery.

The Milken Institute Future of Health Summit brings together global leaders across healthcare, business, technology, and policy to address the most pressing health challenges and opportunities. Cybin's inclusion in this forum reflects the increasing mainstream acceptance of psychedelic-derived medicines as legitimate therapeutic options. Additional information about Cybin's developments is available through the company's newsroom at https://ibn.fm/CYBN. The full press release detailing Dr. Inamdar's participation can be accessed at https://ibn.fm/8AL6L. This high-profile speaking engagement positions Cybin at the forefront of discussions about the future of mental health treatment and underscores the pharmaceutical industry's growing interest in novel neuropsychiatry approaches.